No Picture

Upstream Bio raises $200M in new financing round to get asthma drug to PhIII

Upstream Bio has raised another $200 million to go through Phase II studies and prepare for late-stage trials of an ex-Astellas monoclonal antibody in anticipation of competition with AstraZeneca and Amgen’s asthma drug Tezspire. The raise, disclosed Thursday morning, mirrors its first funding round from 2021 and will bankroll… Click here to view original post… […]